A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019)

N Z Med J. 2020 Apr 3;133(1512):85-87.


There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. We reviewed the available evidence, and have not found this to be the case. We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use.

MeSH terms

  • Angiotensin Receptor Antagonists* / adverse effects
  • Angiotensin Receptor Antagonists* / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors* / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors* / therapeutic use
  • Animals
  • Betacoronavirus
  • COVID-19
  • Consensus
  • Coronavirus Infections* / complications
  • Humans
  • Hypertension* / complications
  • Hypertension* / drug therapy
  • Models, Animal
  • Pandemics*
  • Peptidyl-Dipeptidase A* / drug effects
  • Peptidyl-Dipeptidase A* / metabolism
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / drug therapy
  • Pneumonia, Viral* / prevention & control
  • SARS-CoV-2


  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Peptidyl-Dipeptidase A